Flora Growth (FLGC) Competitors

Flora Growth logo
$2.80 +0.06 (+2.19%)
As of 11/16/2026

FLGC vs. ICU, TMDIF, ARAY, LUCY, and NDRA

Should you buy Flora Growth stock or one of its competitors? Flora Growth's main competitors and comparable companies include SeaStar Medical (ICU), Titan Medical (TMDIF), Accuray (ARAY), Innovative Eyewear (LUCY), and ENDRA Life Sciences (NDRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Flora Growth compare to SeaStar Medical?

SeaStar Medical (NASDAQ:ICU) and Flora Growth (NASDAQ:FLGC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, SeaStar Medical had 9 more articles in the media than Flora Growth. MarketBeat recorded 9 mentions for SeaStar Medical and 0 mentions for Flora Growth. SeaStar Medical's average media sentiment score of 0.04 beat Flora Growth's score of 0.00 indicating that SeaStar Medical is being referred to more favorably in the media.

Company Overall Sentiment
SeaStar Medical Neutral
Flora Growth Neutral

1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 0.7% of SeaStar Medical shares are owned by insiders. Comparatively, 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Flora Growth has a net margin of -32.03% compared to SeaStar Medical's net margin of -678.24%. Flora Growth's return on equity of -64.02% beat SeaStar Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
SeaStar Medical-678.24% -261.10% -149.15%
Flora Growth -32.03%-64.02%-34.46%

SeaStar Medical has higher earnings, but lower revenue than Flora Growth. SeaStar Medical is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeaStar Medical$1.23M3.38-$12.15M-$3.64N/A
Flora Growth$57.61M0.05-$15.91M-$32.49N/A

SeaStar Medical currently has a consensus price target of $8.00, indicating a potential upside of 924.33%. Given SeaStar Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe SeaStar Medical is more favorable than Flora Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SeaStar Medical
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Flora Growth
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

SeaStar Medical has a beta of -1.07, suggesting that its share price is 207% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

Summary

SeaStar Medical and Flora Growth tied by winning 8 of the 16 factors compared between the two stocks.

How does Flora Growth compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and Flora Growth (NASDAQ:FLGC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, Titan Medical's average media sentiment score of 0.00 equaled Flora Growth'saverage media sentiment score.

Company Overall Sentiment
Titan Medical Neutral
Flora Growth Neutral

Titan Medical has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

Titan Medical has higher earnings, but lower revenue than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Titan Medical$17.63M0.52$6.95M$0.051.60
Flora Growth$57.61M0.05-$15.91M-$32.49N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Flora Growth
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Titan Medical has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Titan Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Titan MedicalN/A -82.31% -51.47%
Flora Growth -32.03%-64.02%-34.46%

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 0.0% of Titan Medical shares are held by company insiders. Comparatively, 2.3% of Flora Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Flora Growth beats Titan Medical on 7 of the 12 factors compared between the two stocks.

How does Flora Growth compare to Accuray?

Accuray (NASDAQ:ARAY) and Flora Growth (NASDAQ:FLGC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

In the previous week, Accuray had 3 more articles in the media than Flora Growth. MarketBeat recorded 3 mentions for Accuray and 0 mentions for Flora Growth. Accuray's average media sentiment score of 0.46 beat Flora Growth's score of 0.00 indicating that Accuray is being referred to more favorably in the media.

Company Overall Sentiment
Accuray Neutral
Flora Growth Neutral

64.1% of Accuray shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 3.5% of Accuray shares are held by company insiders. Comparatively, 2.3% of Flora Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Flora Growth has lower revenue, but higher earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accuray$401.95M0.02-$49.19M-$6.00N/A
Flora Growth$57.61M0.05-$15.91M-$32.49N/A

Accuray has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accuray
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Flora Growth
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Accuray has a net margin of -4.41% compared to Flora Growth's net margin of -32.03%. Accuray's return on equity of -35.36% beat Flora Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
Accuray-4.41% -35.36% -3.88%
Flora Growth -32.03%-64.02%-34.46%

Summary

Accuray beats Flora Growth on 10 of the 14 factors compared between the two stocks.

How does Flora Growth compare to Innovative Eyewear?

Flora Growth (NASDAQ:FLGC) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by insiders. Comparatively, 1.8% of Innovative Eyewear shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Flora Growth has a net margin of -32.03% compared to Innovative Eyewear's net margin of -216.76%. Flora Growth's return on equity of -64.02% beat Innovative Eyewear's return on equity.

Company Net Margins Return on Equity Return on Assets
Flora Growth-32.03% -64.02% -34.46%
Innovative Eyewear -216.76%-102.66%-92.20%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flora Growth
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Innovative Eyewear
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

In the previous week, Innovative Eyewear's average media sentiment score of 1.87 beat Flora Growth's score of 0.00 indicating that Innovative Eyewear is being referred to more favorably in the news media.

Company Overall Sentiment
Flora Growth Neutral
Innovative Eyewear Very Positive

Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.75, suggesting that its share price is 175% more volatile than the broader market.

Innovative Eyewear has lower revenue, but higher earnings than Flora Growth. Innovative Eyewear is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flora Growth$57.61M0.05-$15.91M-$32.49N/A
Innovative Eyewear$2.66M2.53-$7.59M-$1.18N/A

Summary

Flora Growth and Innovative Eyewear tied by winning 6 of the 12 factors compared between the two stocks.

How does Flora Growth compare to ENDRA Life Sciences?

Flora Growth (NASDAQ:FLGC) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Flora Growth has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ENDRA Life Sciences has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Flora Growth-32.03% -64.02% -34.46%
ENDRA Life Sciences N/A -178.84%-121.58%

ENDRA Life Sciences has a consensus price target of $25.00, suggesting a potential upside of 498.23%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Flora Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flora Growth
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, ENDRA Life Sciences had 4 more articles in the media than Flora Growth. MarketBeat recorded 4 mentions for ENDRA Life Sciences and 0 mentions for Flora Growth. Flora Growth's average media sentiment score of 0.00 beat ENDRA Life Sciences' score of -0.30 indicating that Flora Growth is being referred to more favorably in the media.

Company Overall Sentiment
Flora Growth Neutral
ENDRA Life Sciences Neutral

ENDRA Life Sciences has lower revenue, but higher earnings than Flora Growth. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flora Growth$57.61M0.05-$15.91M-$32.49N/A
ENDRA Life SciencesN/AN/A-$7.03M-$6.38N/A

Summary

ENDRA Life Sciences beats Flora Growth on 8 of the 14 factors compared between the two stocks.

Get Flora Growth News Delivered to You Automatically

Sign up to receive the latest news and ratings for FLGC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FLGC vs. The Competition

MetricFlora GrowthHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.93M$5.99B$7.83B$11.74B
Dividend YieldN/A1.68%2.47%4.47%
P/E Ratio-0.0938.0634.3128.41
Price / Sales0.055.398.495.70
Price / CashN/A23.6221.0121.90
Price / Book0.234.174.453.72
Net Income-$15.91M$143.92M$3.52B$393.10M
7 Day Performance10.67%-5.44%-5.94%-5.77%
1 Month Performance-30.00%-3.64%-4.59%-7.14%
1 Year Performance-63.23%-0.05%-1.94%-7.47%

Flora Growth Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FLGC
Flora Growth
0.104 of 5 stars
$2.80
+2.2%
N/A-62.4%$2.93M$57.61MN/A280
ICU
SeaStar Medical
3.508 of 5 stars
$1.90
+0.2%
$8.00
+320.2%
-74.2%$10.13M$1.23MN/A17
TMDIF
Titan Medical
N/A$0.08
-0.5%
N/A-82.6%$9.65M$17.63MN/A50
ARAY
Accuray
0.9781 of 5 stars
$3.16
-1.1%
N/A-93.9%$9.43M$401.95MN/A809
LUCY
Innovative Eyewear
1.3257 of 5 stars
$0.84
-3.0%
N/A-52.0%$7.27M$2.66MN/A13

Related Companies and Tools


This page (NASDAQ:FLGC) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners